Teva Pharmaceutical Industries Ltd., of Jerusalem, said the UK's High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Ltd., a subsidiary of Mylan Laboratories Inc., of Pittsburgh

Fibrocell Science Inc., of Exton, Pa., entered a definitive agreement to sell its majority ownership stake in Agera Laboratories Inc., of Exton, Pa., a skin care company offering anti-aging, pigmentation and acne treatment products, to Rohto Pharmaceutical Co

Ranbaxy Laboratories Inc., of Princeton, N.J., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., is planning to launch Absorica (isotretinoin) in the fourth quarter, now that the FDA has approved the drug for the treatment of severe recalcitrant nodular acne

Forest Laboratories Inc., of New York, issued a statement in response to a Form 13D filing from entities affiliated with activist shareholder Carl Icahn stating an intention to nominate a minority slate of candidates to the company's board

Unigene Laboratories Inc., of Boonton, N.J., said preclinical studies of its lead anorexigenic peptide, UGP281, demonstrated a dose-related decrease in body weight of 10 percent to 15 percent when administered subcutaneously in rats and dogs over a seven-day treatment period

Last month, Watson Laboratories Inc., of Corona, Calif., filed an abbreviated new drug application containing a Paragraph IV certification for testosterone gel referring to nine U.S

Watson Pharmaceuticals Inc., of Parsippany, N.J., said that its subsidiary, Watson Laboratories Inc., filed an abbreviated new drug application with the FDA for Mesalamine delayed-release tablets 1.2 g

Discovery Laboratories Inc., of Warrington, Pa., said that in a preclinical study in preterm lamb surfactant deficiency, Surfaxin LS (lyophilized KL4 surfactant) compared favorably to Curosurf in terms of improvements in lung function, and may have a more favorable safety profile

Ironwood Pharmaceuticals Inc., of Cambridge, Mass., and Forest Laboratories Inc., of New York, said the FDA extended the review period for linaclotide in the treatment of irritable bowel syndrome with constipation and chronic constipation (CC) by three months

Auxilium Pharmaceuticals Inc., of Malvern, Pa., and FCB I LLC, of Mahwah, N.J., said they received a notice that Watson Laboratories Inc., of Corona, Calif., filed an abbreviated new drug application containing a Paragraph IV certification for testosterone gel

Impax Laboratories Inc., of Hayward, Calif., confirmed that it has initiated a challenge of the Orange Book patents listed in connection with Gralise (gabapentin tablets) from Depomed Inc., of Menlo Park, Calif., by filing an abbreviated new drug application containing paragraph IV certification for a generic version of the postherpetic neuralgia drug

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, and said the FDA will require a three-month extension to complete its review of the new drug application for aclidinium bromide, a long-acting antimuscarinic drug, for the maintenance treatment of chronic obstructive pulmonary disease

Forest Laboratories Inc., of New York, said it has acquired all U.S

Forest Laboratories Inc., of New York, and Almirall SA, of Barcelona, Spain, said the FDA will require a three-month extension to complete its review of the new drug application for aclidinium bromide, a long-acting antimuscarinic drug, for the maintenance treatment of chronic obstructive pulmonary disease

rights for aclidinium to Forest Laboratories Inc., of New York, which is jointly involved in the compound's development

Watson Pharmaceuticals Inc., of Parsippany, N.J., said its subsidiary Watson Laboratories Inc

Watson Pharmaceuticals Inc., Parsippany, N.J., said its subsidiary filed an abbreviated new drug application for Nebivolol hydrochloride tablets, a generic version of New York-based Forest Laboratories Inc.'s Bystolic, a beta-adrenergic blocking agent for use in hypertension

Columbia Laboratories Inc., of Livingston, N.J., engaged Cowen and Co

Pierre Fabre Medicament, of Castres, France, and Forest Laboratories Inc., of New York, reported top-line results in a Phase III trial showing that levomilnacipran significantly reduced depression symptoms in patients with major depressive disorder compared to placebo, as early as week one and at each subsequent visit, as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated